PALB2 Knockout BT-549 Cell Line

The choice depends on whether you are studying PALB2 (partner and localizer of BRCA2)'s role as a tumor suppressor and BRCA-pathway scaffold or modeling familial breast cancer susceptibility 2 (FANCN). The Knockout line is the standard tool for asking whether PALB2 is required for BRCA2 recruitment to DNA damage sites and homologous recombination repair — PALB2 bridges BRCA1 to BRCA2, organizing the HR repair machinery. Overexpression is useful for studying PALB2 in HR repair or for testing pathogenic mutations. For breast cancer research, the EDITGENE PALB2 Knockout in BT-549 is highly relevant — BT-549 is a triple-negative breast cancer (TNBC) cell line, and PALB2 mutations confer breast/ovarian cancer susceptibility comparable to BRCA2. Biallelic PALB2 mutations cause Fanconi anemia type N. PARP inhibitor (olaparib, talazoparib) sensitivity is enhanced in PALB2-deficient cells — the knockout is a critical specificity control for PARP inhibitor pharmacology and for HR deficiency studies. Disease variant rescue enables genotype-function studies.

Primary applications: • Homologous recombination repair: HR reporter assays (DR-GFP), RAD51 foci analysis, and γH2AX kinetics following DNA double-strand break induction. • PARP inhibitor sensitivity: olaparib, talazoparib, niraparib dose-response analysis in PALB2-null versus rescued TNBC context — clinically relevant for HR deficiency-targeted therapy. • Familial cancer modeling: rescue with patient-derived PALB2 mutations for genotype-function studies of breast/ovarian cancer susceptibility. • BRCA pathway scaffolding: BRCA1-PALB2-BRCA2 complex assembly analysis by co-immunoprecipitation. EDITGENE recommends this model for researchers investigating BRCA pathway biology, HR repair deficiency, PARP inhibitor pharmacology, and familial breast cancer mechanisms.

Yes. PALB2 rescue experiments are well-established for HR repair research: • Construct design: use a codon-modified PALB2 sequence with a small C-terminal tag (FLAG, HA). PALB2 has N-terminal coiled-coil (BRCA1 binding), DNA-binding ChAM domain, MRG15-binding domain, and C-terminal WD40 (BRCA2 binding) — preserve all elements. • BRCA1-binding-deficient rescue: N-terminal coiled-coil mutations disrupt BRCA1 binding without affecting BRCA2 interaction. • BRCA2-binding-deficient rescue: WD40 domain mutations disrupt BRCA2 binding. • Patient mutation rescue: familial breast cancer PALB2 mutations enable disease genotype-function studies. • Functional readout: rescue should restore HR repair efficiency (DR-GFP), RAD51 foci formation, and PARP inhibitor resistance. BT-549 transduces with lentivirus at moderate efficiency; optimization may be needed.